Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events.
about
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradationThe PCSK9 decadeTrafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainThe multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functionsPhysiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liverLow density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.Selection of DNA aptamers with two modified bases.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors.Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.Studies of the autoinhibitory segment comprising residues 31-60 of the prodomain of PCSK9: Possible implications for the mechanism underlying gain-of-function mutations.Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradationSRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serum.
P2860
Q24294486-EC674FF4-3E75-41E9-9C94-F9CEAFB19766Q24615397-51F8FE1F-3D4F-463D-A531-6809BC7A28B5Q27339783-AE16BD31-2DEB-4D5D-97F5-CAC8E7AE42EFQ30541820-E537E860-55A4-4A53-A811-53B4C367AFEAQ33599961-51804015-B452-4349-BCB5-64CE95352DD7Q34433146-A478C964-8EC9-422C-B3B0-1515D255B33DQ34458693-9B410E1E-D77D-434A-8AE9-F591AC7F3E0DQ34479132-02AD21A6-A2B4-4BD0-B4E1-E8C9A6BFAF5AQ34723257-51459DD5-62C5-4121-BB7D-FF71615C1747Q34951227-28D0F6C1-7F95-48ED-8BDF-F900E922C857Q35768386-964EF867-4D72-4580-8C41-332ABBF90962Q35883857-75124A7F-1E5F-4A68-A227-9B23D803DC10Q36520700-14548B3F-E39E-4BC9-AA6A-86977AE3A4CAQ36708550-FDD3CDAB-53FA-4993-96F5-44B998CBAB26Q36866980-6B3A1B1C-E396-44A6-817F-DA4EA6D67C94Q37711632-F952F802-F994-4179-9A1A-EB1D9D2C743AQ38109960-03615DB4-3736-4D1F-BA80-5407E2B02B7FQ38151675-AAC727C5-3685-4153-9A72-F2F97D9D0FEDQ38415736-BD40D86E-D2C6-4DC4-B3E5-DD617CD21251Q38855416-E118F8A8-062A-419D-B31C-238837AB7205Q39146866-A16F54BB-DB83-48F6-B2D6-DB02BBE43FA4Q41020560-4207EE28-814A-4281-B780-DE7555E959F6Q41851719-DDF91953-19E7-42C3-95D7-232F0E74A2ADQ42136107-185ADEC6-9113-4BC6-AB66-AD8AEB87FAA0Q51305608-B83990D8-6FA6-44AC-8DE3-10DC58D97E13
P2860
Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Effects of the prosegment and ...... additional processing events.
@en
type
label
Effects of the prosegment and ...... additional processing events.
@en
prefLabel
Effects of the prosegment and ...... additional processing events.
@en
P2093
P2860
P356
P1476
Effects of the prosegment and ...... additional processing events.
@en
P2093
Bowman Miao
Franck Duclos
Gaétan Mayer
Gerald Duke
Josée Hamelin
Marie-Claude Asselin
Peter Lemaire
Rachid Essalmani
Rex Parker
Suzanne Benjannet
P2860
P304
40965-40978
P356
10.1074/JBC.M110.154815
P407
P577
2010-10-11T00:00:00Z